Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 26

1.

In vitro activity of a novel broad-spectrum antifungal, E1210, tested against Aspergillus spp. determined by CLSI and EUCAST broth microdilution methods.

Pfaller MA, Duncanson F, Messer SA, Moet GJ, Jones RN, Castanheira M.

Antimicrob Agents Chemother. 2011 Nov;55(11):5155-8. doi: 10.1128/AAC.00570-11. Epub 2011 Aug 15.

2.

In vitro activity of a novel broad-spectrum antifungal, E1210, tested against Candida spp. as determined by CLSI broth microdilution method.

Pfaller MA, Hata K, Jones RN, Messer SA, Moet GJ, Castanheira M.

Diagn Microbiol Infect Dis. 2011 Oct;71(2):167-70. doi: 10.1016/j.diagmicrobio.2011.05.001. Epub 2011 Jun 22.

PMID:
21696907
3.
4.

Candida bloodstream infections: comparison of species distribution and resistance to echinocandin and azole antifungal agents in Intensive Care Unit (ICU) and non-ICU settings in the SENTRY Antimicrobial Surveillance Program (2008-2009).

Pfaller MA, Messer SA, Moet GJ, Jones RN, Castanheira M.

Int J Antimicrob Agents. 2011 Jul;38(1):65-9. doi: 10.1016/j.ijantimicag.2011.02.016. Epub 2011 Apr 22.

PMID:
21514797
6.

Candida bloodstream infections: comparison of species distributions and antifungal resistance patterns in community-onset and nosocomial isolates in the SENTRY Antimicrobial Surveillance Program, 2008-2009.

Pfaller MA, Moet GJ, Messer SA, Jones RN, Castanheira M.

Antimicrob Agents Chemother. 2011 Feb;55(2):561-6. doi: 10.1128/AAC.01079-10. Epub 2010 Nov 29.

7.
8.

Declining antimicrobial susceptibility of Streptococcus pneumoniae in the United States: report from the SENTRY Antimicrobial Surveillance Program (1998-2009).

Jones RN, Sader HS, Moet GJ, Farrell DJ.

Diagn Microbiol Infect Dis. 2010 Nov;68(3):334-6. doi: 10.1016/j.diagmicrobio.2010.08.024. No abstract available.

PMID:
20955919
9.

Variation in Candida spp. distribution and antifungal resistance rates among bloodstream infection isolates by patient age: report from the SENTRY Antimicrobial Surveillance Program (2008-2009).

Pfaller MA, Castanheira M, Messer SA, Moet GJ, Jones RN.

Diagn Microbiol Infect Dis. 2010 Nov;68(3):278-83. doi: 10.1016/j.diagmicrobio.2010.06.015. Epub 2010 Sep 16.

PMID:
20846808
10.

Worldwide summary of telavancin spectrum and potency against Gram-positive pathogens: 2007 to 2008 surveillance results.

Putnam SD, Sader HS, Moet GJ, Mendes RE, Jones RN.

Diagn Microbiol Infect Dis. 2010 Aug;67(4):359-68. doi: 10.1016/j.diagmicrobio.2010.03.009.

PMID:
20638605
11.
12.

In vitro activity of telavancin against a contemporary worldwide collection of Staphylococcus aureus isolates.

Mendes RE, Moet GJ, Janechek MJ, Jones RN.

Antimicrob Agents Chemother. 2010 Jun;54(6):2704-6. doi: 10.1128/AAC.00301-10. Epub 2010 Apr 12.

13.

Comparison of European Committee on Antimicrobial Susceptibility Testing (EUCAST) and Etest methods with the CLSI broth microdilution method for echinocandin susceptibility testing of Candida species.

Pfaller MA, Castanheira M, Diekema DJ, Messer SA, Moet GJ, Jones RN.

J Clin Microbiol. 2010 May;48(5):1592-9. doi: 10.1128/JCM.02445-09. Epub 2010 Mar 24.

14.

Antimicrobial activity of daptomycin tested against Staphylococcus aureus with vancomycin MIC of 2 microg/mL isolated in the United States and European hospitals (2006-2008).

Sader HS, Becker HK, Moet GJ, Jones RN.

Diagn Microbiol Infect Dis. 2010 Mar;66(3):329-31. doi: 10.1016/j.diagmicrobio.2009.09.017.

PMID:
20159377
15.

Antimicrobial resistance among Gram-positive bacteria isolated in Latin American hospitals.

Sader HS, Moet GJ, Jones RN.

J Chemother. 2009 Dec;21(6):611-20.

PMID:
20071283
16.

CEM-101, a novel fluoroketolide: antimicrobial activity against a diverse collection of Gram-positive and Gram-negative bacteria.

Putnam SD, Castanheira M, Moet GJ, Farrell DJ, Jones RN.

Diagn Microbiol Infect Dis. 2010 Apr;66(4):393-401. doi: 10.1016/j.diagmicrobio.2009.10.013.

PMID:
20022192
17.

Expanded studies of piperacillin/tazobactam formulations: variations among branded product lots and assessment of 46 generic lots.

Moet GJ, Watters AA, Sader HS, Jones RN.

Diagn Microbiol Infect Dis. 2009 Nov;65(3):319-22. doi: 10.1016/j.diagmicrobio.2009.06.012.

PMID:
19822271
19.

TR-700 in vitro activity against and resistance mutation frequencies among Gram-positive pathogens.

Jones RN, Moet GJ, Sader HS, Mendes RE, Castanheira M.

J Antimicrob Chemother. 2009 Apr;63(4):716-20. doi: 10.1093/jac/dkp021. Epub 2009 Feb 13.

PMID:
19218276
20.

In vitro potency evaluations of various piperacillin/tazobactam generic products compared with the contemporary branded (Zosyn, Wyeth) formulation.

Jones RN, Fritsche TR, Moet GJ.

Diagn Microbiol Infect Dis. 2008 May;61(1):76-9. doi: 10.1016/j.diagmicrobio.2007.12.010. Epub 2008 Jan 24. Erratum in: Diagn Microbiol Infect Dis. 2008 Jul;61(3):366-8.

PMID:
18221852
21.

Antimicrobial resistance and molecular epidemiology of vancomycin-resistant enterococci from North America and Europe: a report from the SENTRY antimicrobial surveillance program.

Deshpande LM, Fritsche TR, Moet GJ, Biedenbach DJ, Jones RN.

Diagn Microbiol Infect Dis. 2007 Jun;58(2):163-70. Epub 2007 Mar 26.

PMID:
17368801
22.

Contemporary causes of skin and soft tissue infections in North America, Latin America, and Europe: report from the SENTRY Antimicrobial Surveillance Program (1998-2004).

Moet GJ, Jones RN, Biedenbach DJ, Stilwell MG, Fritsche TR.

Diagn Microbiol Infect Dis. 2007 Jan;57(1):7-13. Epub 2006 Oct 23.

PMID:
17059876
23.

Tigecycline (GAR-936) activity against Streptococcus gallolyticus (bovis) and viridans group streptococci.

Moet GJ, Dowzicky MJ, Jones RN.

Diagn Microbiol Infect Dis. 2007 Mar;57(3):333-6. Epub 2006 Sep 20.

PMID:
16989974
24.
26.

Potential utility of a peptide deformylase inhibitor (NVP PDF-713) against oxazolidinone-resistant or streptogramin-resistant Gram-positive organism isolates.

Jones RN, Moet GJ, Sader HS, Fritsche TR.

J Antimicrob Chemother. 2004 May;53(5):804-7. Epub 2004 Mar 31.

PMID:
15056649

Supplemental Content

Support Center